AEMD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AE

Mkt Cap

$3.7M

Volume

34.32K

Next Earnings

November 11th

Loading chart

AE

AEMDAETHLON MEDICAL INC

AEMD

Pay with—

Available Balance0.00

AE

Mkt Cap

$3.7M

Volume

34.32K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB ReviewAethlon Medical announced that its independent Data Safety Monitoring Board (DSMB) has recommended advancing to the third and final cohort of its clinical trial for the Hemopurifier device. The DSMB found no safety concerns in the second cohort data, with no serious adverse events or dose-limiting toxicities reported. The final cohort will enroll 9-18 patients receiving three treatments over one week at three Australian clinical sites.Benzinga · Mar 24, 2026

Totaligent Executes Binding LOI for Joint Venture and Acquisition of GloMed SolutionsTotaligent Inc. (OTC: TGNT) announced the execution of a binding Letter of Intent with GloMed Solutions, a Japanese medical aesthetics and biologics distributor generating ~$10M in annual revenue. The agreement establishes a joint venture integrating Totaligent's Aetherium Medical platform with GloMed's operations, while granting Totaligent a binding call option to fully acquire GloMed within one year. The JV is targeted to close around March 22, 2026, positioning the company in the rapidly growing biologics and medical tourism sectors.Benzinga · Feb 25, 2026

Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026Aethlon Medical (NASDAQ: AEMD), a medical therapeutic company developing the Hemopurifier device for cancer and infectious disease treatment, announced it will release fiscal Q3 2025 financial results on February 12, 2026, at 4:15 p.m. ET, followed by a management conference call at 4:30 p.m. ET. The Hemopurifier has received FDA Breakthrough Device designations for advanced/metastatic cancer and life-threatening viral infections.Benzinga · Feb 4, 2026

Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAsAethlon Medical published preclinical study showing their Hemopurifier device can bind and remove extracellular vesicles from Long COVID patient samples, potentially decreasing inflammatory microRNAs and offering a novel therapeutic approach.Benzinga · Dec 2, 2025

Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate UpdateAethlon Medical reported Q2 2025 financial results, highlighting clinical progress in oncology trials, ongoing Long COVID research, and significant cost reductions of 48% in operating expenses.Benzinga · Nov 12, 2025

Correction to Previous Release: “Promeza MG Works with AETH to Support its LS25 Predicación y Migración Conference”Promeza MG has been contracted by AETH to provide marketing services for a theological conference addressing migration, preaching, and pastoral care, taking place in October 2025 at Life Pacific University.GlobeNewswire Inc. · Sep 30, 2025

Aethlon Medical Announces Pricing of $4.5 Million Public OfferingAethlon Medical has priced a public offering of 5 million shares and warrants at $0.90 per share, expecting to raise approximately $4.5 million for general corporate purposes including clinical trials and research.Benzinga · Sep 4, 2025

Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 13, 2025Aethlon Medical will release its fiscal Q1 2025 financial results on August 13, hosting a conference call to discuss financial performance and recent corporate developments, focusing on their Hemopurifier medical device for treating cancer and infectious diseases.Benzinga · Aug 5, 2025

Aethlon Medical Announces Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate UpdateAethlon Medical reported financial results for Q4 2025, highlighting progress in cancer trials with Hemopurifier® device, receiving Indian regulatory approval, and reducing operating expenses while advancing research in oncology and Long COVID.Benzinga · Jun 26, 2025

Presenting on Emerging Growth Conference 83 Day 2 on June 18; Register to live streamEmergingGrowth.com announces the schedule for the 83rd Emerging Growth Conference on June 17-18, 2025, featuring presentations from various companies in growth sectors.GlobeNewswire Inc. · Jun 17, 2025

to start trading

AE

AEMDAETHLON MEDICAL INC

AEMD

Pay with—

Available Balance0.00

Your PositionYou don't own any AEMD yet.

Related Tickers

Earnings